JPWO2022014640A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022014640A5 JPWO2022014640A5 JP2022536420A JP2022536420A JPWO2022014640A5 JP WO2022014640 A5 JPWO2022014640 A5 JP WO2022014640A5 JP 2022536420 A JP2022536420 A JP 2022536420A JP 2022536420 A JP2022536420 A JP 2022536420A JP WO2022014640 A5 JPWO2022014640 A5 JP WO2022014640A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen atom
- alkyl group
- antitumor agent
- group optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 17
- -1 pyrimidine compound Chemical class 0.000 claims 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229940000425 combination drug Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- KJWHUTTYFUQYBW-WAOWUJCRSA-N 4-amino-6-(2-cyclopropylethynyl)-7-[(3R,5S)-5-methyl-1-prop-2-enoylpyrrolidin-3-yl]-N-[(1R)-1-phenylethyl]pyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound C(C=C)(=O)N1C[C@@H](C[C@@H]1C)N1C(=C(C2=C1N=CN=C2N)C(=O)N[C@H](C)C1=CC=CC=C1)C#CC1CC1 KJWHUTTYFUQYBW-WAOWUJCRSA-N 0.000 claims 2
- ZJRNPKQLORKDSN-YQVWRLOYSA-N 4-amino-7-[(3R,5S)-5-methyl-1-prop-2-enoylpyrrolidin-3-yl]-N-[(1R)-1-phenylethyl]-6-prop-1-ynylpyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound C(C=C)(=O)N1C[C@@H](C[C@@H]1C)N1C(=C(C2=C1N=CN=C2N)C(=O)N[C@H](C)C1=CC=CC=C1)C#CC ZJRNPKQLORKDSN-YQVWRLOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- UDTMKUKLYSHHHD-QKNQBKEWSA-N 4-amino-6-(3,3-dimethylbut-1-ynyl)-7-[(3R,5S)-5-methyl-1-prop-2-enoylpyrrolidin-3-yl]-N-[(1R)-1-phenylethyl]pyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound C(C=C)(=O)N1C[C@@H](C[C@@H]1C)N1C(=C(C2=C1N=CN=C2N)C(=O)N[C@H](C)C1=CC=CC=C1)C#CC(C)(C)C UDTMKUKLYSHHHD-QKNQBKEWSA-N 0.000 claims 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 229960003962 trifluridine Drugs 0.000 claims 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020121733 | 2020-07-15 | ||
| JP2020121733 | 2020-07-15 | ||
| PCT/JP2021/026462 WO2022014640A1 (ja) | 2020-07-15 | 2021-07-14 | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022014640A1 JPWO2022014640A1 (cg-RX-API-DMAC10.html) | 2022-01-20 |
| JPWO2022014640A5 true JPWO2022014640A5 (cg-RX-API-DMAC10.html) | 2023-03-27 |
| JP7373664B2 JP7373664B2 (ja) | 2023-11-02 |
Family
ID=79554846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022536420A Active JP7373664B2 (ja) | 2020-07-15 | 2021-07-14 | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230255972A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4183395A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7373664B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230031926A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021308045B2 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202216151A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022014640A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492208B2 (en) * | 2020-07-15 | 2025-12-09 | Taiho Pharmaceutical Co., Ltd. | Crystal of pyrimidine compound |
| AU2022282261A1 (en) * | 2021-05-24 | 2023-12-21 | Taiho Pharmaceutical Co., Ltd. | Treatment methods for subjects with cancer having an aberration in egfr and/or her2 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| PT669929E (pt) | 1992-11-13 | 2007-04-30 | Immunex Corp | Ligando de elk, uma citoquina |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| BR9408323A (pt) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Derivados de rapamicina |
| EP0756627A1 (en) | 1994-04-15 | 1997-02-05 | Amgen Inc. | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| EP0922030A1 (en) | 1996-08-23 | 1999-06-16 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
| HUP0000852A2 (hu) | 1997-02-03 | 2001-05-28 | Pfizer Products Inc. | Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
| US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
| TR200000368T2 (tr) | 1997-08-08 | 2000-07-21 | Pfizer Products Inc. | Ariloksiariarilsülfonilamino hidroksamik asit türevleri. |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| NZ516258A (en) | 1999-06-07 | 2004-02-27 | Immunex Corp | Tek antagonists |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| US7074408B2 (en) | 2000-02-25 | 2006-07-11 | Immunex Corporation | Use of integrin antagonists to inhibit angiogenesis |
| CA2531454C (en) | 2003-07-08 | 2011-10-25 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
| EP1648900A4 (en) | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | PHOSPHORUS MACROCYCLES |
| TW200523262A (en) | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| JP4242911B2 (ja) | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
| TW200626610A (en) | 2004-10-13 | 2006-08-01 | Wyeth Corp | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101267824A (zh) | 2005-09-20 | 2008-09-17 | 辉瑞产品公司 | 使用酪氨酸激酶抑制剂的治疗剂型和方法 |
| WO2007067781A2 (en) * | 2005-12-08 | 2007-06-14 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| CN103459400B (zh) | 2011-04-06 | 2016-05-18 | 大鹏药品工业株式会社 | 咪唑并噁嗪化合物或其盐 |
| AU2013210403B2 (en) * | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| MX360498B (es) * | 2013-08-12 | 2018-11-05 | Taiho Pharmaceutical Co Ltd | Compuesto novedoso de pirimidina fusionada o sal del mismo. |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| KR102075886B1 (ko) * | 2015-09-01 | 2020-02-11 | 다이호야쿠힌고교 가부시키가이샤 | 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염 |
| TWI623316B (zh) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
| DK3269370T3 (da) * | 2016-02-23 | 2020-04-06 | Taiho Pharmaceutical Co Ltd | Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf |
| SG11201809223PA (en) * | 2016-04-19 | 2018-11-29 | Univ California | Erbb inhibitors and uses thereof |
| MA52421A (fr) | 2018-03-02 | 2021-01-06 | Otsuka Pharma Co Ltd | Composés pharmaceutiques |
| MA53395A (fr) | 2018-07-24 | 2021-06-02 | Otsuka Pharma Co Ltd | Composés hétérobicycliques pour inhiber l'activité de shp2 |
| PL3909584T3 (pl) * | 2019-01-11 | 2024-03-25 | Taiho Pharmaceutical Co., Ltd. | Związek pirymidynowy lub jego sól |
| JP7275603B2 (ja) | 2019-01-29 | 2023-05-18 | 凸版印刷株式会社 | チューブ容器 |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| KR102873219B1 (ko) * | 2020-07-15 | 2025-10-17 | 다이호야쿠힌고교 가부시키가이샤 | Egfr 저해제 |
-
2021
- 2021-07-14 TW TW110125847A patent/TW202216151A/zh unknown
- 2021-07-14 WO PCT/JP2021/026462 patent/WO2022014640A1/ja not_active Ceased
- 2021-07-14 EP EP21841448.0A patent/EP4183395A4/en not_active Withdrawn
- 2021-07-14 US US18/015,616 patent/US20230255972A1/en active Pending
- 2021-07-14 JP JP2022536420A patent/JP7373664B2/ja active Active
- 2021-07-14 AU AU2021308045A patent/AU2021308045B2/en active Active
- 2021-07-14 KR KR1020237003587A patent/KR20230031926A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022014639A5 (cg-RX-API-DMAC10.html) | ||
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| TWI791467B (zh) | 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）、奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）、５-氟尿嘧啶及甲醯四氫葉酸（ｌｅｕｃｏｖｏｒｉｎ）之組合療法治療胃癌 | |
| JP2019516733A5 (cg-RX-API-DMAC10.html) | ||
| JP6364546B2 (ja) | 抗腫瘍剤の副作用軽減剤 | |
| JP2005533748A5 (cg-RX-API-DMAC10.html) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| US11065240B2 (en) | Drug combinations to treat multiple myeloma | |
| ZA200502753B (en) | Use of the quinazoline derivative ZD6747 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| RU2018128796A (ru) | Противоопухолевое средство, содержащее иммуномодулятор и усилитель противоопухолевого эффекта | |
| FI3909584T3 (fi) | Pyrimidiiniyhdiste tai sen suola | |
| JP2020523354A5 (cg-RX-API-DMAC10.html) | ||
| CN1424912A (zh) | 用于治疗癌症的含有喜树碱和嘧啶衍生物的组合物 | |
| JP2013511526A5 (cg-RX-API-DMAC10.html) | ||
| JP2018522049A5 (cg-RX-API-DMAC10.html) | ||
| JP6845332B2 (ja) | がん治療用医薬組成物及びその使用 | |
| JP2024505252A (ja) | Ｐｔｅｎ不活性化突然変異を有する患者における癌の治療 | |
| JP2013510866A (ja) | 組み合わせたチボザニブおよびテムシロリムス | |
| US20250114353A1 (en) | Combination Treatment Regimens - SMARCA2 Degrader With Gemcitabine | |
| CN120154618B (zh) | 格索雷塞用于治疗肺癌的用途或其药物组合物 | |
| JPWO2010131460A1 (ja) | テガフール・ギメラシル・オテラシルカリウム配合剤及びオキサリプラチンを含有する抗腫瘍剤 | |
| TH2101004042A (th) | สารประกอบไพริมิดีนหรือเกลือของสารประกอบดังกล่าว | |
| EP4676478A1 (en) | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy | |
| JP5581200B2 (ja) | シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤 |